Terms: = Kidney tumors AND TFE3, RCCP2, 7030, ENSG00000068323, TFEA AND Treatment
64 results:
1. Genomic alterations and diagnosis of renal cancer.
Zhang X; Bolck HA; Rupp NJ; Moch H
Virchows Arch; 2024 Feb; 484(2):323-337. PubMed ID: 37999735
[TBL] [Abstract] [Full Text] [Related]
2. High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma.
Lang M; Schmidt LS; Wilson KM; Ricketts CJ; Sourbier C; Vocke CD; Wei D; Crooks DR; Yang Y; Gibbs BK; Zhang X; Klumpp-Thomas C; Chen L; Guha R; Ferrer M; McKnight C; Itkin Z; Wangsa D; Wangsa D; James A; Difilippantonio S; Karim B; Morís F; Ried T; Merino MJ; Srinivasan R; Thomas CJ; Linehan WM
J Exp Clin Cancer Res; 2023 Apr; 42(1):99. PubMed ID: 37095531
[TBL] [Abstract] [Full Text] [Related]
3. Clear cell renal cell carcinoma with cystic component similar to multilocular cystic renal neoplasm of low malignant potential: a rare pattern of cyst-dependent progression from multilocular cystic renal neoplasm of low malignant potential.
Yang B; Sun L; Cao WF; Qi LS; Guo YH; Sun Y
Diagn Pathol; 2023 Feb; 18(1):27. PubMed ID: 36810118
[TBL] [Abstract] [Full Text] [Related]
4. A case report and literature review on nephrogenic alveolar soft part sarcoma: clinicopathological manifestations and genetic features.
Wang X; Yu J; Fan X; Ma S; Xie X; Gao N; Huang S; Lu A
BMC Urol; 2023 Feb; 23(1):17. PubMed ID: 36782230
[TBL] [Abstract] [Full Text] [Related]
5. MiT/TFE Family Renal Cell Carcinoma.
Tang J; Baba M
Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672892
[TBL] [Abstract] [Full Text] [Related]
6. Clinicopathologic, treatment and prognosis study of 46 Xp11.2 translocation/tfe3 gene fusion renal cell carcinomas.
Zhou J; Zhao L; Yang Z; Chen Y; Wu X; Xue W
BMC Urol; 2022 Jul; 22(1):109. PubMed ID: 35850864
[TBL] [Abstract] [Full Text] [Related]
7. Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamide-chlorambucil conjugate.
Funasaki S; Mehanna S; Ma W; Nishizawa H; Kamikubo Y; Sugiyama H; Ikeda S; Motoshima T; Hasumi H; Linehan WM; Schmidt LS; Ricketts C; Suda T; Oike Y; Kamba T; Baba M
Cancer Sci; 2022 Jul; 113(7):2352-2367. PubMed ID: 35396773
[TBL] [Abstract] [Full Text] [Related]
8. Renal cancer associated with Xp11.2 translocation/tfe3 gene fusion: Clinicopathological analysis of 13 cases.
Feng R; Tao Y; Chen Y; Xu W; Zhang G; Wang H
Ann Diagn Pathol; 2022 Jun; 58():151908. PubMed ID: 35149286
[TBL] [Abstract] [Full Text] [Related]
9. Phenotypical screening on metastatic PRCC-tfe3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agents.
Cao C; Lan X; Shang B; Jiang W; Guo L; Zheng S; Bi X; Zhou A; Sun Z; Shou J
Clin Transl Oncol; 2022 Jul; 24(7):1333-1346. PubMed ID: 35118587
[TBL] [Abstract] [Full Text] [Related]
10. Integrated exome and RNA sequencing of tfe3-translocation renal cell carcinoma.
Sun G; Chen J; Liang J; Yin X; Zhang M; Yao J; He N; Armstrong CM; Zheng L; Zhang X; Zhu S; Sun X; Yang X; Zhao W; Liao B; Pan X; Nie L; Yang L; Chen Y; Zhao J; Zhang H; Dai J; Shen Y; Liu J; Huang R; Liu J; Wang Z; Ni Y; Wei Q; Li X; Zhou Q; Huang H; Liu Z; Shen P; Chen N; Zeng H
Nat Commun; 2021 Sep; 12(1):5262. PubMed ID: 34489456
[TBL] [Abstract] [Full Text] [Related]
11. mTOR Inhibition Increases Transcription Factor E3 (tfe3) Activity and Modulates Programmed Death-Ligand 1 (PD-L1) Expression in Translocation Renal Cell Carcinoma.
Lee HJ; Shin DH; Song JS; Park JY; Kim SY; Hwang CS; Na JY; Lee JH; Kim JY; Park SW; Sol MY
Am J Pathol; 2021 Nov; 191(11):1999-2008. PubMed ID: 34358517
[TBL] [Abstract] [Full Text] [Related]
12. Autophagy in Xp11 translocation renal cell carcinoma: from bench to bedside.
Sun H; Wei X; Zeng C
Mol Cell Biochem; 2021 Dec; 476(12):4231-4244. PubMed ID: 34345999
[TBL] [Abstract] [Full Text] [Related]
13. Multidrug refractory aggressive metastatic tfe3 (+) renal cell carcinoma: A case report.
Paksoy N; Erdem S; Karaca M; Ak N; Pehlivan M; Yirgin IK; Ozluk Y; Ekiz F; Tural D; Ekenel M; Ozcan F; Basaran M
J Oncol Pharm Pract; 2022 Jan; 28(1):215-221. PubMed ID: 34134568
[TBL] [Abstract] [Full Text] [Related]
14. EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma.
Tatjana A; Tjota MY; O'Donnell PH; Eggener SE; Agarwal PK; Haridas R; Segal J; Wang P
Virchows Arch; 2022 Feb; 480(2):487-492. PubMed ID: 34128116
[TBL] [Abstract] [Full Text] [Related]
15. Nuclear translocation of ASPL-tfe3 fusion protein creates favorable metabolism by mediating autophagy in translocation renal cell carcinoma.
Fang R; Wang X; Xia Q; Zhao M; Zhang H; Wang X; Ye S; Cheng K; Liang Y; Cheng Y; Gu Y; Rao Q
Oncogene; 2021 May; 40(18):3303-3317. PubMed ID: 33846569
[TBL] [Abstract] [Full Text] [Related]
16. Sunitinib treatment promotes metastasis of drug-resistant renal cell carcinoma via tfe3 signaling pathway.
Li L; Zhao S; Liu Z; Zhang N; Pang S; Liu J; Liu C; Fan Y
Cell Death Dis; 2021 Feb; 12(2):220. PubMed ID: 33637706
[TBL] [Abstract] [Full Text] [Related]
17. [Clinicopathological analysis of clear cell renal cell carcinoma with hemangioblastoma component].
Huang HJ; Chen MJ; Li XO; Zhong DR
Zhonghua Bing Li Xue Za Zhi; 2021 Feb; 50(2):103-107. PubMed ID: 33535303
[No Abstract] [Full Text] [Related]
18. Characteristics and outcome of pediatric renal cell carcinoma patients registered in the International Society of Pediatric Oncology (SIOP) 93-01, 2001 and UK-IMPORT database: A report of the SIOP-Renal Tumor Study Group.
van der Beek JN; Hol JA; Coulomb-l'Hermine A; Graf N; van Tinteren H; Pritchard-Jones K; Houwing ME; de Krijger RR; Vujanic GM; Dzhuma K; Schenk JP; Littooij AS; Ramírez-Villar GL; Murphy D; Ray S; Al-Saadi R; Gessler M; Godzinski J; Ruebe C; Collini P; Verschuur AC; Frisk T; Vokuhl C; Hulsbergen-van de Kaa CA; de Camargo B; Sandstedt B; Selle B; Tytgat GAM; van den Heuvel-Eibrink MM
Int J Cancer; 2021 Jun; 148(11):2724-2735. PubMed ID: 33460450
[TBL] [Abstract] [Full Text] [Related]
19. tfe3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
Schmiester M; Dolnik A; Kornak U; Pfitzner B; Hummel M; Treue D; Hartmann A; Agaimy A; Weyerer V; Lekaj A; Brakemeier S; Peters R; Öllinger R; Märdian S; Bullinger L; Striefler JK; Flörcken A
J Pathol Clin Res; 2021 Jan; 7(1):3-9. PubMed ID: 33180365
[TBL] [Abstract] [Full Text] [Related]
20. tfe3-PD-L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma.
Guo X; Li R; Bai Q; Jiang S; Wang H
J Cell Mol Med; 2020 Dec; 24(24):14441-14452. PubMed ID: 33145941
[TBL] [Abstract] [Full Text] [Related]
[Next]
